Canurta Sharpens Its Commercial Model for the Next Phase of Growth
Advancing Our Commercial Strategy
Canurta is moving from research-led innovation toward a more structured commercial model, while preserving our longer-term therapeutic ambitions.
Dear Canurta Community,
The science behind Canurta remains our foundation. What is evolving is how we bring that innovation to market.
We’re sharpening our focus across two distinct pathways: advancing our therapeutic research while building consumer health products through Canurta Naturals.
This month, we’re sharing progress on our commercial strategy, U.S. market relationships and the priorities for our next phase.
01 / OUR STRATEGY
One Research Foundation. Two Pathways to Market.
This structure allows us to pursue commercial opportunities on different timelines while building on a shared foundation of research and intellectual property.
02 / COMMERCIAL PROGRESS
Dual Relief™ Enters the U.S. Market
Our first consumer brand, Dual Relief™, is now available through its U.S. online store.
Previously introduced under the PolyKye name, Dual Relief™ now has its own consumer identity, featuring our proprietary Hemp Flavonoid Complex™.
This marks an important step in our commercialization strategy. A direct-to-consumer channel gives us an opportunity to understand customer demand, build brand awareness and gather insights to guide future innovation.
03 / BUSINESS DEVELOPMENT
Expanding Our U.S. Network
Canurta continues to build relationships across the U.S. innovation and investment ecosystem.
LOS ANGELES | OCTOBER 12–15
We joined the SoCal–Canadian Black Tech Express delegation during LA Tech Week, connecting with investors, founders and potential U.S. collaborators.
CHICAGO | OCTOBER 20
Akeem participated in Chicago Venture Summit: Future of Health, connecting Canurta with leaders across the health innovation and investment community.
These engagements support our efforts to increase visibility, explore strategic relationships and better understand opportunities for U.S. expansion.
04 / LEADERSHIP
Strengthening Commercial Leadership
Together, these capabilities support Canurta’s transition from research-led innovation toward a more structured commercial operating model.
06 / WHAT’S NEXT
What’s Next
Over the coming weeks, our Dual Relief in Market series will provide a closer look at our research, commercial activities and what we’re learning as we bring innovation to market.
Thank you for your continued support as we build Canurta’s next chapter.
The Canurta Team
